Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2025 Filed Apr 3, 2025 16:59 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 64 | $222.86 | $14,263.04 |
DisclosureSEC source: 0001127602-25-011320 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,846 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 11, 2024. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 01:56 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,000 | $230.36 | $230,360.00 |
DisclosureSEC source: 0001127602-25-009188 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,864 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:19 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,589 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0001127602-25-009051 · form4.xml · derivative · entry 10 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 3,589 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:19 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,882 | $0.00 Strike: $211.76 | $0.00 |
DisclosureSEC source: 0001127602-25-009051 · form4.xml · derivative · entry 9 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 5,882 shares Expires 2027-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:19 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock Options · Derivative | 105 | $0.00 Strike: $211.76 | $0.00 |
DisclosureSEC source: 0001127602-25-009051 · form4.xml · derivative · entry 8 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 105 shares Expires 2027-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:19 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock Options · Derivative | 169 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0001127602-25-009051 · form4.xml · derivative · entry 7 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 169 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:19 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
SaleResMed Common Stock | 9,745 | $239.31 | $2,332,096.41 |
DisclosureSEC source: 0001127602-25-009051 · form4.xml · nonDerivative · entry 5 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,725 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $236.62 - $242.73. The price reported above reflects the weighted average sale price. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:19 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock | 5,882 | $211.76 | $1,245,572.32 |
DisclosureSEC source: 0001127602-25-009051 · form4.xml · nonDerivative · entry 4 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:19 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock | 3,589 | $146.34 | $525,214.26 |
DisclosureSEC source: 0001127602-25-009051 · form4.xml · nonDerivative · entry 3 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:19 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock | 105 | $211.76 | $22,234.80 |
DisclosureSEC source: 0001127602-25-009051 · form4.xml · nonDerivative · entry 2 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:19 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock | 169 | $146.34 | $24,731.46 |
DisclosureSEC source: 0001127602-25-009051 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 15:04 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,009 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001127602-25-008958 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,074 Underlying: ResMed Common Stock · 8,009 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 15:04 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 8,009 | $229.20 | $1,835,692.43 |
DisclosureSEC source: 0001127602-25-008958 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,472 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $223.64 - $232.39. The price reported above reflects the weighted average sale price. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 15:04 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 8,009 | $101.64 | $814,034.76 |
DisclosureSEC source: 0001127602-25-008958 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 22:40 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $227.71 | $455,420.00 |
DisclosureSEC source: 0001127602-25-008593 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,218 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,726 | $0.00 Strike: $211.76 | $0.00 |
DisclosureSEC source: 0001127602-25-007977 · form4.xml · derivative · entry 12 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,882 Underlying: ResMed Common Stock · 4,726 shares Expires 2027-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock Options · Derivative | 514 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0001127602-25-007977 · form4.xml · derivative · entry 11 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169 Underlying: ResMed Common Stock · 514 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,506 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0001127602-25-007977 · form4.xml · derivative · entry 10 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,589 Underlying: ResMed Common Stock · 3,506 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock Options · Derivative | 367 | $0.00 Strike: $211.76 | $0.00 |
DisclosureSEC source: 0001127602-25-007977 · form4.xml · derivative · entry 9 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105 Underlying: ResMed Common Stock · 367 shares Expires 2027-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
SaleResMed Common Stock | 4,726 | $235.43 | $1,112,623.75 |
DisclosureSEC source: 0001127602-25-007977 · form4.xml · nonDerivative · entry 8 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,725 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $235.00 - $236.18. The price reported above reflects the weighted average sale price. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
SaleResMed Common Stock | 514 | $235.25 | $120,917.78 |
DisclosureSEC source: 0001127602-25-007977 · form4.xml · nonDerivative · entry 7 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,451 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $235.00 - $236.18. The price reported above reflects the weighted average sale price. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
SaleResMed Common Stock | 3,506 | $235.40 | $825,308.19 |
DisclosureSEC source: 0001127602-25-007977 · form4.xml · nonDerivative · entry 6 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,965 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $235.00 - $236.18. The price reported above reflects the weighted average sale price. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
SaleResMed Common Stock | 367 | $235.25 | $86,336.24 |
DisclosureSEC source: 0001127602-25-007977 · form4.xml · nonDerivative · entry 5 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,471 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $235.00 - $236.18. The price reported above reflects the weighted average sale price. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock | 4,726 | $211.76 | $1,000,777.76 |
DisclosureSEC source: 0001127602-25-007977 · form4.xml · nonDerivative · entry 4 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock | 514 | $146.34 | $75,218.76 |
DisclosureSEC source: 0001127602-25-007977 · form4.xml · nonDerivative · entry 3 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock | 3,506 | $146.34 | $513,068.04 |
DisclosureSEC source: 0001127602-25-007977 · form4.xml · nonDerivative · entry 2 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:25 UTC |
Ghoshal KaushikChief Commercial Officer, SaaS
|
Exercise / conversionResMed Common Stock | 367 | $211.76 | $77,715.92 |
DisclosureSEC source: 0001127602-25-007977 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · Chief Commercial Officer, SaaS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:51 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 64 | $234.10 | $14,982.40 |
DisclosureSEC source: 0001127602-25-007943 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,910 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 11, 2024. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 17:55 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,000 | $238.98 | $238,980.00 |
DisclosureSEC source: 0001127602-25-004042 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,864 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 17:54 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,009 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001127602-25-004041 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,083 Underlying: ResMed Common Stock · 8,009 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 17:54 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 8,009 | $236.77 | $1,896,306.95 |
DisclosureSEC source: 0001127602-25-004041 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,472 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $235.74 - $238.67 The price reported above reflects the weighted average sale price. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 17:54 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 8,009 | $101.64 | $814,034.76 |
DisclosureSEC source: 0001127602-25-004041 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| February 05, 2025 Filed Feb 5, 2025 21:49 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $242.11 | $484,220.00 |
DisclosureSEC source: 0001127602-25-003232 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,218 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 17:18 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 64 | $242.42 | $15,514.88 |
DisclosureSEC source: 0001127602-25-002880 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,974 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 11, 2024. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:52 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,000 | $234.04 | $234,040.00 |
DisclosureSEC source: 0001127602-25-001067 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,864 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:57 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $230.99 | $461,980.00 |
DisclosureSEC source: 0001127602-25-000487 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,218 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:52 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 75 | $230.99 | $17,324.25 |
DisclosureSEC source: 0001127602-25-000486 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,038 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 11, 2024. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 18:17 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,000 | $244.23 | $244,230.00 |
DisclosureSEC source: 0001127602-24-029095 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,864 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 6, 2024. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 23:44 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $245.65 | $491,300.00 |
DisclosureSEC source: 0001127602-24-028741 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,218 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024 Read SEC document |
| December 02, 2024 Filed Dec 2, 2024 23:02 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 74 | $248.91 | $18,419.34 |
DisclosureSEC source: 0001127602-24-028324 · form4.xml · nonDerivative · entry 2 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,113 F2 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted May 11, 2024. Read SEC document |
| November 29, 2024 Filed Dec 2, 2024 23:02 UTC |
Rider Michael JGlobal General Counsel
|
GiftResMed Common Stock | 173 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028324 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,187 F1 · kind: Gift of shares to Fidelity Charitable, a donor advised fund. Mr. Rider has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| November 27, 2024 Filed Nov 27, 2024 20:19 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 2,000 | $249.67 | $499,330.00 |
DisclosureSEC source: 0001127602-24-028165 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Lisette and Michael Farrell Foundation Disclosed balance after: 0 Read SEC document |
| November 27, 2024 Filed Nov 27, 2024 20:19 UTC |
Farrell Michael J.Chief Executive Officer
|
GiftResMed Common Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028165 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Lisette and Michael Farrell Foundation Disclosed balance after: 2,000 F2 · kind: Gift of shares transferred from The Lisette and Michael Farrell Family Trust, Mr. Farrell retains dispositive power over the gifted shares. Read SEC document |
| November 27, 2024 Filed Nov 27, 2024 20:19 UTC |
Farrell Michael J.Chief Executive Officer
|
GiftResMed Common Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028165 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Lisette and Michael Farrell Family Trust Disclosed balance after: 2,090 F1 · kind: Gift of shares transferred to The Lisette and Michael Farrell Family Foundation, Mr. Farrell retains dispositive power over remaining shares. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 00:49 UTC |
FARRELL PETER CDirector
|
GrantResMed Common Stock Options · Derivative | 1,468 | $249.56 Strike: $249.56 | $366,354.08 |
DisclosureSEC source: 0001127602-24-028139 · form4.xml · derivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,468 Underlying: ResMed Common Stock · 1,468 shares Expires 2031-11-25 F1 · derivative.exercise_date: Represents date options first became exercisable. Options vest on the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first (1st) annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 20:19 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock Options · Derivative | 33,036 | $249.56 Strike: $249.56 | $8,244,464.16 |
DisclosureSEC source: 0001127602-24-028165 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,036 Underlying: ResMed Common Stock · 33,036 shares Expires 2031-11-25 F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| November 22, 2024 Filed Nov 25, 2024 16:14 UTC |
Leong JustinChief Product Officer
|
SaleReMed Common Stock | 6,160 | $243.09 | $1,497,415.92 |
DisclosureSEC source: 0001127602-24-027960 · form4.xml · nonDerivative · entry 1 Leong Justin · CIK 0001825782 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,718 F1 · price: This transaction was executed in multiple trades at prices ranging from $243.00 - $243.315. The price reported above reflects the weighted average sale price. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:26 UTC |
TAYLOR RONALD RDirector
|
GrantResMed Common Stock | 1,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-027906 · form4.xml · nonDerivative · entry 1 TAYLOR RONALD R · CIK 0001161920 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,698 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2025, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:25 UTC |
Tan DesneyDirector
|
GrantResMed Common Stock | 1,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-027905 · form4.xml · nonDerivative · entry 1 Tan Desney · CIK 0001890548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,929 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2025, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:24 UTC |
SULPIZIO RICHARDDirector
|
GrantResMed Common Stock | 1,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-027904 · form4.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,796 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2025, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.